Cargando…
Literature review and expert opinion on the impact of achondroplasia on medical complications and health-related quality of life and expectations for long-term impact of vosoritide: a modified Delphi study
BACKGROUND: Achondroplasia is associated with disproportionate short stature and significant and potentially severe medical complications. Vosoritide is the first medicine to treat the underlying cause of achondroplasia and data from phase 3 and phase 2 extension studies showed effects on growth and...
Autores principales: | Savarirayan, Ravi, Baratela, Wagner, Butt, Thomas, Cormier-Daire, Valérie, Irving, Melita, Miller, Bradley S., Mohnike, Klaus, Ozono, Keiichi, Rosenfeld, Ron, Selicorni, Angelo, Thompson, Dominic, White, Klane K., Wright, Michael, Fredwall, Svein O. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9195406/ https://www.ncbi.nlm.nih.gov/pubmed/35698202 http://dx.doi.org/10.1186/s13023-022-02372-z |
Ejemplares similares
-
Pharmacokinetics and Exposure–Response of Vosoritide in Children with Achondroplasia
por: Chan, Ming Liang, et al.
Publicado: (2021) -
Parents’ Experience of Administering Vosoritide: A Daily Injectable for Children with Achondroplasia
por: NiMhurchadha, Sinead, et al.
Publicado: (2023) -
SAT-LB18 A Randomized Controlled Trial of Vosoritide in Children With Achondroplasia
por: Savarirayan, Ravi, et al.
Publicado: (2020) -
LBMON196 A Randomized Controlled Trial Of Vosoritide In Infants And Toddlers With Achondroplasia
por: Savarirayan, Ravi, et al.
Publicado: (2022) -
Evidence of feedback regulation of C-type natriuretic peptide during Vosoritide therapy in Achondroplasia
por: Prickett, Timothy C. R., et al.
Publicado: (2021)